137219-37-5
Chemical Structure
Plitidepsin
Synonym(s): Aplidine; PM90001
- CAS No.: 137219-37-5
- Formula:C57H87N7O15
- Molecular Weight:1110.34
IUPAC Name: (S)-N-((R)-1-(((3S,6R,7S,10R,11S,15S,17S,20S,25aS)-10-((S)-sec-butyl)-11-hydroxy-20-isobutyl-15-isopropyl-3-(4-methoxybenzyl)-2,6,17-trimethyl-1,4,8,13,16,18,21-heptaoxodocosahydro-15H-pyrrolo[2,1-f][1,15]dioxa[4,7,10,20]tetraazacyclotricosin-7-yl)amino)-4-methyl-1-oxopentan-2-yl)-N-methyl-1-(2-oxopropanoyl)pyrrolidine-2-carboxamide
InChIKey: UUSZLLQJYRSZIS-LXNNNBEUSA-N
SMILES: O=C([C@@H](NC([C@H](C([C@@H](OC(C[C@@H]1O)=O)C(C)C)=O)C)=O)CC(C)C)N(CCC2)[C@]2([H])C(N([C@H](C(O[C@@H]([C@@H](C(N[C@]1([H])[C@@H](C)CC)=O)NC([C@@H](CC(C)C)N(C)C([C@H](CCC3)N3C(C(C)=O)=O)=O)=O)C)=O)CC(C=C4)=CC=C4OC)C)=O
Biological Activity: Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( KD=80 nM)[1]. Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC90 of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Plitidepsin | 99.91% | Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( KD=80 nM). Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC90 of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Plitidepsin (Standard) | ≥98% | Plitidepsin (Standard) is the analytical standard of Plitidepsin. This product is intended for research and analytical applications. Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( KD=80 nM). Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC90 of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Alejandro Losada, et al. Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin. Sci Rep. 2016 Oct 7;6:35100. [Content Brief]
- [2]. Kris M White, et al. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science. 2021 Feb 26;371(6532):926-931. [Content Brief]
